Boron-containing carbonic anhydrases inhibitors

Giovannuzzi, Simone; Nikitjuka, Anna; Pereira Resende, Bruna Rafaela; Smietana, Michael; Nocentini, Alessio; Supuran, Claudiu T.; Winum, Jean-Yves

doi:10.1016/j.bioorg.2023.106976

Cited by 7 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding nephropathy, no clear studies exploring BCC in the kidneys of diabetic patients have been reported. However it is well-known that these compounds exert effects in nephron remodeling[ 84 ], probably by acting in some enzymes (such as carbonic anhydrase)[ 85 , 86 ]; additionally, they have been used to treat commonly associated maladies, such as lithiasis[ 87 ].…”

Section: Bcc As Potential Agents In Diabetes Complicationsmentioning

confidence: 99%

Boron-containing compounds as labels, drugs, and theranostic agents for diabetes and its complications

Soriano-Ursúa,

Cordova-Chávez,

Farfan-García

et al. 2024

World J Diabetes

View full text Add to dashboard Cite

Diabetes is a disease with a high global burden. Current strategies have failed to limit the advancement and impact of the disease. Successful early diagnosis and treatment will require the development of new agents. In this sense, boron-containing compounds have been reported as agents with the ability to reduce glycemia and lipidemia. They have also been used for labeling and measuring carbohydrates and other molecules linked to the initial stages of diabetes and its progression. In addition, certain boron compounds bind to molecules related to diabetes development and their biological activity in the regulation of elevated glycemia. Finally, it should be noted that some boron compounds appear to exert beneficial effects on diabetes complications such as accelerating wound healing while ameliorating pain in diabetic patients.

show abstract